Prasugrel by Default in ACS Patients Post-PCI Lowers Bleeding With No Ischemic Penalty

SWITCH-SWEDEHEART’s unique design randomized healthcare regions but wasn’t a head-to-head comparison with ticagrelor.

Prasugrel by Default in ACS Patients Post-PCI Lowers Bleeding With No Ischemic Penalty

MUNICH, Germany—When prasugrel is considered the default antiplatelet choice for patients with acute coronary syndromes who undergo PCI, fewer major bleeding events occur than if the default had been ticagrelor, according to results from the registry-based SWITCH-SWEDEHEART study. Moreover, this benefit does not come at the expense of more ischemic events.

The findings were presented today at the European Society of Cardiology (ESC) Congress 2026 by Elmir Omerovic, MD, PhD (Sahlgrenska University Hospital and University of Gothenburg, Sweden), and simultaneously published in the New England Journal of Medicine.

“Prasugrel and ticagrelor have been recommended over clopidogrel for years,” Omerovic said at an ESC press conference. The TRITON-TIMI 38 and PLATO trials, respectively, cemented their use. However, with the arrival of the ISAR-REACT 5 trial in 2020 showing prasugrel to be superior to ticagrelor, European guidelines for ACS management were updated to reflect that shift. Moreover, costs of the two evolved over time as prasugrel went generic in Europe in 2018.

Yet, as Omerovic and colleagues note in NEJM, “whether the findings from the ISAR-REACT 5 trial are generalizable to routine practice is uncertain.” Thus, they sought to understand which of the two potent P2Y12 inhibitors held an edge for outcomes as the default drug shifted.

Omerovic stressed that this study was not a head-to-head comparison but rather a policy-level perspective that, by virtue of its design, provides a window into how much sway clinical recommendations have in influencing practice.

In Sweden, he explained, the administrative structure for healthcare and medical education is decentralized, with each region’s council being responsible for that area. “The recommendations come from the boards . . . every year,” said Omerovic. Another key characteristic of Sweden, he said with a smile, is that “we mostly follow the recommendations.”

Drug Policy Eras Analyzed

SWITCH-SWEDEHEART investigators leveraged the Swedish healthcare system to compare the two medications. Seven out of 21 regions took part, representing about half of the country’s population. All initially started out with local regulators recommending ticagrelor as the first choice and then switched, as three clusters in a randomly assigned order, to prioritizing prasugrel between 2021 and 2024.

Recommended maintenance doses were 90 mg twice daily for ticagrelor and 10 mg daily (reduced to 5 mg for patients older than 70 years and those weighing less than 60 kg) with prasugrel.

“By randomizing the default policy rather than individual drug assignment, the trial preserved the protection of randomization while incorporating clinician-directed exceptions, contraindications, and treatment selection as they occur in practice,” the researchers note, adding that if anything, such a design would “understate a true between-drug difference.”

Subsequently, they analyzed national registry data for the 17,095 patients (mean age 69.8 years; 27.8% female) undergoing PCI for ACS in those regions during the course of the study: 55% received care under a default ticagrelor policy and 45% under a default prasugrel policy. Nearly four in 10 of those patients presented with STEMI, 43.7% with NSTEMI, and 16.8% with unstable angina. Angiographic and procedural characteristics were similar in the ticagrelor and prasugrel policy eras.

After excluding the patients who died within a week of their admission without receiving postdischarge medications, 93.5% of those treated under the ticagrelor policy and 94.2% of those treated under the prasugrel policy received a P2Y12 inhibitor.

The choice of drug did not always follow policy: 75.8% of patients received prasugrel as recommended and 60.6% received ticagrelor as recommended. Most of those treated in contrast to policy received clopidogrel, though 10% of those treated during the prasugrel policy eras in fact received ticagrelor. Some also switched agents after starting: 12.7% of those who received ticagrelor as recommended and 8.7% of those who received prasugrel as recommended ultimately shifted to another P2Y12 inhibitor.

By 1-year follow-up, the primary endpoint of death, MI, or stroke had occurred in 11.1% of the prasugrel-policy group and 11.8% of the ticagrelor-policy group (adjusted OR 0.90; 95% CI 0.77-1.06). Major bleeding rates were 4.2% and 4.4%, respectively (adjusted OR 0.80; 95% CI 0.64-0.99).

“With equal protection against major events and less major bleeding, the overall balance favors prasugrel as the first-choice recommendation in routine care,” Omerovic concluded.

The paper further notes: “The findings from the current SWITCH-SWEDEHEART trial refine, rather than contradict, the existing evidence.”

Novel and Pragmatic

Roxana Mehran, MD (Icahn School of Medicine at Mount Sinai, New York, NY), current president of the American College of Cardiology, told TCTMD that the trial could not be replicated in the United States because physicians would push back on a policy if it wasn’t aligned with their current practice. “They’re not really comparing one drug versus the other, they’re comparing the mode of changing from one drug to the other,” she commented. “It’s about the sites and how they did, instead of the molecule.”

The difference in bleeding, added Mehran, may relate to the ability to reduce the prasugrel dose as needed. 

Randomized trials have confirmed ticagrelor does work well, she specified. “I think the only reason to switch over to prasugrel is if the patient is noncompliant with the BID dosing. I don’t really think that one is better than the other.”

Mehran, who also was the discussant following Omerovic’s presentation in the Hot Line Session, praised SWITCH-SWEDEHEART for its novelty and pragmatic design. “This has been a 20-year journey. . . . So the idea of bringing this forward is tremendously beneficial,” she said, adding that the results must be interpreted with nuance given that it was the policy—not the treatment itself—that was randomized.

“So, the question I would keep in mind is not whether this was well done, [as] it clearly was,” but whether it allows for comparison between the two agents, Mehran suggested.

Even with the strengths and limitations in mind, the trial’s “clinical implications are totally clear: either agent remains a defensible regional default in an unselected patient population,” she said. A more relevant issue now is how best to pursue antiplatelet de-escalation, added Mehran. 

Caitlin E. Cox is Executive Editor of TCTMD and Associate Director, Editorial Content at the Cardiovascular Research Foundation. She produces the…

Read Full Bio
Sources
Disclosures
  • The study was sponsored and funded by Region Västra Götaland, Sweden.
  • Omerovic reports no relevant conflicts of interest.

Comments